# A Study of Pazopanib With CAPEOX in AGC Patients

> **NCT01130805** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 66 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Pazopanib in combination with capecitabine and oxaliplatin

## Key facts

- **NCT ID:** NCT01130805
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130805, "A Study of Pazopanib With CAPEOX in AGC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01130805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*